biostudies-literatureMonastirioti ABristol Myers Squibb International Corporation (BMS)4739https://www.ebi.ac.uk/biostudies/studies/S-EPMC9564103biostudies-literatureUnknown14(19)Since circulating microRNAs (miRNAs) are involved in the modulation of the immune response, they are tested as liquid biopsy-based biomarkers in patients with NSCLC treated with immunotherapy. We analyzed the expression levels and examined the clinical significance of immunoregulatory miRNAs involved in immune checkpoint regulation (miR-34a, miR-200b, miR-200c), T-cell activity (miR-155), and the function of myeloid-derived suppressive cells (MDSCs) (miR-223) or regulatory T lymphocytes (Tregs) (miR-146a), in patients with advanced NSCLC (N = 69) treated with anti-PD-1 (Nivolumab) immunotherapy as 2nd or 3rd line of treatment therapy. Plasma levels of circulating miRNAs were analyzed by RT-qPCR before the initiation of immunotherapy. Expression of miR-34a, miR-146a, mir-200c, and miR-223 wCancersPlasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.PMC9564103CA209-8NXKalapanida DPapadaki MAMavroudis DRounis KAgelaki SMichaelidou KMonastirioti APapadaki CfalsePlasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.Since circulating microRNAs (miRNAs) are involved in the modulation of the immune response, they are tested as liquid biopsy-based biomarkers in patients with NSCLC treated with immunotherapy. We analyzed the expression levels and examined the clinical significance of immunoregulatory miRNAs involved in immune checkpoint regulation (miR-34a, miR-200b, miR-200c), T-cell activity (miR-155), and the function of myeloid-derived suppressive cells (MDSCs) (miR-223) or regulatory T lymphocytes (Tregs) (miR-146a), in patients with advanced NSCLC (N = 69) treated with anti-PD-1 (Nivolumab) immunotherapy as 2nd or 3rd line of treatment therapy. Plasma levels of circulating miRNAs were analyzed by RT-qPCR before the initiation of immunotherapy. Expression of miR-34a, miR-146a, mir-200c, and miR-223 w2022-01-01T00:00:00Z2022 Sep2025-04-19T06:43:13.537Z2025-04-19T06:43:13.537ZS-EPMC95641033623065810.3390/cancers14194739